These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16785697)

  • 1. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
    Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
    Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
    AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of HIV screening of blood donations in Accra (Ghana).
    van Hulst M; Sagoe KW; Vermande JE; van der Schaaf IP; van der Tuuk Adriani WP; Torpey K; Ansah J; Mingle JA; Smit Sibinga CT; Postma MJ
    Value Health; 2008; 11(5):809-19. PubMed ID: 18489518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit analysis of hepatitis a vaccination in Thailand.
    Teppakdee A; Tangwitoon A; Khemasuwan D; Tangdhanakanond K; Suramaethakul N; Sriratanaban J; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):118-27. PubMed ID: 12118439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the population level effects of an HIV-1 vaccine in an era of highly active antiretroviral therapy.
    Rida W; Sandberg S
    Bull Math Biol; 2009 Apr; 71(3):648-80. PubMed ID: 19214640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
    Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
    Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.